BCM
Bayesian Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.85M | Buy |
+38,600
| New | +$4.85M | 0.77% | 18 |
|
|
2024
Q2 | – | Sell |
-12,453
| Closed | -$1.72M | – | 970 |
|
|
2024
Q1 | $1.72M | Buy |
12,453
+3,800
| +44% | +$524K | 0.16% | 180 |
|
|
2023
Q4 | $1.14M | Buy |
+8,653
| New | +$1.14M | 0.12% | 208 |
|
|
2023
Q1 | – | Sell |
-3,500
| Closed | -$418K | – | 989 |
|
|
2022
Q4 | $418K | Buy |
+3,500
| New | +$418K | 0.06% | 400 |
|
|
2022
Q2 | – | Sell |
-8,713
| Closed | -$817K | – | 976 |
|
|
2022
Q1 | $817K | Buy |
+8,713
| New | +$817K | 0.12% | 252 |
|
|
2020
Q4 | – | Sell |
-4,600
| Closed | -$442K | – | 600 |
|
|
2020
Q3 | $442K | Buy |
+4,600
| New | +$442K | 0.11% | 254 |
|
|
2020
Q1 | – | Sell |
-14,184
| Closed | -$1.53M | – | 912 |
|
|
2019
Q4 | $1.53M | Buy |
+14,184
| New | +$1.53M | 0.26% | 95 |
|
|
2018
Q4 | – | Sell |
-3,109
| Closed | -$382K | – | 724 |
|
|
2018
Q3 | $382K | Buy |
+3,109
| New | +$382K | 0.06% | 389 |
|
|
2018
Q1 | – | Sell |
-11,340
| Closed | -$880K | – | 744 |
|
|
2017
Q4 | $880K | Buy |
11,340
+6,874
| +154% | +$533K | 0.18% | 193 |
|
|
2017
Q3 | $274K | Buy |
+4,466
| New | +$274K | 0.07% | 385 |
|